BRD4 and hepatocellular carcinoma: As the active part in the SF1126 prodrug, LY294002 combines with BRD4 and prevents BRD4 from interacting with acetylated histone-H4 proteins on chromatin, thus replacing BRD4 coactivator proteins from the transcriptional start site of MYC in the Huh7 and SK-Hep1 HCC cell lines (Mahadevan et al., 2012; Singh et al., 2016).